Anika Therapeutics, Inc.

NASDAQ:ANIK

Medical - Devices

Healthcare
$13.62 -0.39%

-$0.06 today

Market cap
$182.44M
Beta
0.23
P/E (TTM)
-17.3
EPS (TTM)
-$0.82
52W Low $7.87High $16.24

Volume 0.12M

Average 0.11M

ANIK Depreciation & Amortization

Non-cash asset write-downs added back to net income because no cash left the business.

Anika Therapeutics, Inc.NASDAQ: ANIK

Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026

Depreciation & amortization declines year over year

Q1 FY2026 depreciation & amortization of $1.41M fell 11.6% year over year, ahead of the -27.5% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 6.8% from the prior quarter. Over 3 fiscal years it compounded at -26.6% a year.

Context

  • Depreciation & amortization amounted to 5.1% of revenue in FY2025, down 1.7 pp from a year earlier.
  • Depreciation & amortization increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of -11.6% holds above the trailing-twelve-month pace of -27.5%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$1.41M+6.8% QoQ
Last fiscal yearDec 2025
$5.73M-29.5% YoY
LTMMar 2026
$5.54M-27.5% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-11.6%——
1 year-29.5%——
3-year CAGR-26.6%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the cash flow

Latest · FY2025
5.73M USD
Year-over-year change
-29.5%
4-year CAGR
-20.5%

Depreciation & Amortization vs competitors

How ANIK compares with its peers on the latest reported figures

  • ANIK's LTM Mar 2026 depreciation & amortization of $5.54M is the 2nd largest of the 9 companies compared; the peer median is $2.4M.
  • Its year-over-year change of -27.5% is the 8th highest of 9, against a peer median of +9.7%.
  • Depreciation & amortization amounts to 4.8% of revenue for ANIK, versus a peer median of 9.0%.
ANIK Competitors Peer median
Depreciation & Amortization for ANIK and competitors
Company Period LTM YoY 3-year CAGR% of revenue
LUCDLucid Diagnostics Inc.LTM Mar 2026$429.44M +48315.3%-23.3%8364.7%
ANIKAnika Therapeutics, Inc.LTM Mar 2026$5.54M -27.5%-26.6%4.8%
MXCTMaxCyte, Inc.LTM Mar 2026$4.68M +4.5%+24.0%14.5%
LNSRLENSAR, Inc.LTM Mar 2026$4.56M +11.6%+9.7%7.9%
RPIDRapid Micro Biosystems, Inc.LTM Mar 2026$3.11M -8.6%+4.7%9.0%
AVRAnteris Technologies Global Corp.LTM Mar 2026$1.69M +7.8%+29.0%91.1%
APYXApyx Medical CorporationLTM Mar 2026$719K +24.0%-9.7%1.3%
OWLTOwlet, Inc.LTM Mar 2026$627K -41.1%-39.6%0.6%
ANIXAnixa Biosciences, Inc.LTM Apr 2026$75K +150.0%——
Peer median (excluding ANIK) $2.4M+9.7%+4.7%9.0%

Competitors are the stored peer set for ANIK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income4.13M(14.86M)(82.67M)(56.39M)(10.88M)
Depreciation & Amortization14.32M14.49M14.22M8.12M5.73M
Deferred Income Tax(1.77M)(5.27M)(6.33M)260K(7K)
Stock-Based Compensation11.09M14.32M15.24M13.13M10.08M
Change in Working Capital(14.72M)(11.82M)(12.12M)(13.09M)(823K)
Accounts Receivables(6.22M)(5.63M)(1.31M)3.37M408K
Inventory(6.62M)(6.87M)(11.4M)(9.42M)30K
Accounts Payables(1.1M)1.97M(11K)(2.51M)42K
Other Working Capital(783K)(1.28M)589K(4.53M)(1.3M)
Other Non-Cash Items(4.66M)7.56M69.87M53.37M7.09M
Operating Cash Flow8.4M4.41M(1.79M)5.4M11.19M
Capital Expenditures(5.14M)(7.49M)(5.43M)(7.73M)(6.83M)
Acquisitions (Net)(476K)0008.99M
Purchases of Investments00000
Sales of Investments2.5M0000
Other Investing Activities000(600K)(2.57M)
Investing Cash Flow(3.12M)(7.49M)(5.43M)(8.33M)(401K)
Debt Repayment(201K)(284K)000
Common Stock Issued1.13M681K00500K
Common Stock Repurchased00(5M)(10.91M)(9.49M)
Dividends Paid00000
Other Financing Activities(7.71M)(5.25M)(1.32M)(1.82M)(1.57M)
Financing Cash Flow(6.78M)(4.85M)(6.32M)(12.73M)(10.55M)
Effect of Forex Changes69K(130K)79K(48K)86K
Net Change in Cash(1.43M)(8.06M)(13.46M)(15.71M)322K
Free Cash Flow3.25M(3.08M)(7.22M)(2.33M)4.36M

Anika Therapeutics, Inc.

NASDAQ:ANIK

Intrinsic Alpha fair value

Locked

Current Price

$13.62

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.